Hypertriglyceridemia Therapeutics Market
Hypertriglyceridemia is a common disorder in which the triglyceride levels in the body increase. It is often caused or exacerbated by uncontrolled diabetes mellitus, obesity, and sedentary habits, all of which are more prevalent in industrialized societies than in developing nations. This rising levels of triglyceride are majorly associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. Hypertriglyceridemia also causes pancreatitis, atherosclerosis, and other cardiovascular diseases. Currently, the advancements in treatment of hypertriglyceridemia are helping in recovering the triglyceride levels in the human body. Severe hypertriglyceridemia means your triglycerides are 500 mg/dL or higher. People with severe hypertriglyceridemia face an increased risk of acute pancreatitis. This is a pancreatic inflammation that needs medical attention. Most people with hypertriglyceridemia have no symptoms. People with severe hyperglyceridemia may develop xanthomas. These are skin bumps that form when lipids build up under your skin. The xanthomas usually appear around your eyelids. But they may also appear on your knees, elbows or palms of your hands. Genetics- increased triglyceride levels in the blood may be associated with certain genetic diseases or disorders, such as familial combined hyperlipidemia.
Market Dynamics
The ongoing research & development of developing novel drugs is expected to propel the global hypertriglyceridemia market growth during the forecast period. Further, growing prevalence of cardiovascular diseases such as atherosclerosis, hypertension, and coronary heart disease and sedentary lifestyle is also expected to boost the global hypertriglyceridemia therapeutics market over the forecast period. For instance, in February 2020, Esperion Therapeutics, Inc., a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol-lowering therapies, announced that the U.S. Food and Drug Administration (FDA) approved NEXLETOL (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.
Key features of the study:
Detailed Segmentation:
Table of Contents
*Browse 32 market data tables and 26 figures on “Global Hypertriglyceridemia Therapeutics Market”- Global forecast to 2030
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients